Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
May 21, 2018 16:30 ET
|
Arcturus Therapeutics, Inc.
Board of Directors Recommends Removal of Terminated CEO Joseph Payne from Board of Directors SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (Arcturus or the Company)...
Arcturus Therapeutics Files Form 20-F
May 14, 2018 17:33 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced the filing of the Company’s Annual Report on Form 20-F for the...
Arcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities Laws
April 20, 2018 08:00 ET
|
Arcturus Therapeutics, Inc.
Complaint Details Multiple Violations of Federal Securities Laws by Undisclosed Group Led by Payne SAN DIEGO, April 20, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading...
Arcturus Therapeutics Issues Statement Regarding Timing of Extraordinary General Meeting of Shareholders
April 08, 2018 10:08 ET
|
Arcturus Therapeutics, Inc.
Postponement due to Joseph Payne’s Focus on Advancing His Personal Agenda at the Expense of Arcturus Shareholders SAN DIEGO, April 08, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd....
Arcturus Therapeutics Issues Open Letter to Shareholders
March 28, 2018 09:04 ET
|
Arcturus Therapeutics, Inc.
Details Former President and CEO Joseph E. Payne’s Poor Judgment, Failed Leadership and Deceit that Led to His Termination for Cause Cites Payne’s Self-Dealing and Blatant Disloyalty to Arcturus, its...
Arcturus Therapeutics Initiates Lawsuit Against Joseph E. Payne to Protect the Interests of Arcturus Shareholders
March 27, 2018 22:37 ET
|
Arcturus Therapeutics, Inc.
Complaint Details Extensive Misconduct by Mr. Payne during Tenure as CEO Cites Mr. Payne’s Self-Dealing and Inappropriate Business Conflicts of Interest SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE)...
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
March 11, 2018 20:00 ET
|
Arcturus Therapeutics, Inc.
Board of Directors Recommends Removal of Terminated CEO Joseph Payne from Board of Directors SAN DIEGO, March 11, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (Arcturus or the Company)...
Arcturus Therapeutics Calls on Proposed Director Nominees to Respond to Constructive Board Outreach
March 05, 2018 23:54 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today issued the following statement regarding the previously announced...
Arcturus Therapeutics Issues Statement Regarding Extraordinary General Meeting of Shareholders
February 26, 2018 23:30 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today announced that, based on the preliminary vote count provided by its...
Arcturus Therapeutics Comments on Amended 13D Filing
February 16, 2018 08:00 ET
|
Arcturus Therapeutics, Inc.
SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today commented on the amended 13D filing by Joseph E. Payne, who was fired...